|
- Drugs (psychoactive) - World Health Organization (WHO)
The use of psychoactive drugs without medical supervision is associated with significant health risks and can lead to the development of drug use disorders Drug use disorders, particularly when untreated, increase morbidity and mortality risks for individuals, can trigger substantial suffering and lead to impairment in personal, family, social, educational, occupational or other important
- WHO Drug Information
About WHO Drug Information WHO Drug Information is a quarterly journal providing an overview of topics relating to medicines development and regulation which is targeted to a wide audience of health professionals and policy makers Launched in 1987, WHO Drug Information communicates the latest international news and trends to regulatory agencies, academic and training institutions, researchers
- Alcohol, Drugs and Addictive Behaviours
The Unit works globally to improve health and well-being of populations by articulating, promoting, supporting and monitoring evidence-informed policies, strategies and interventions to reduce the burden associated with alcohol, drugs and addictive behaviours
- WHO launches new framework to tackle drug resistance to HIV, hepatitis . . .
WHO has released the Integrated drug resistance action framework for HIV, hepatitis B and C and sexually transmitted infections, 2026–2030, a landmark roadmap to address the growing threat of drug resistance and safeguard progress toward ending AIDS and the epidemics of hepatitis B, hepatitis C and sexually transmitted infections (STIs) as public health concerns
- Anatomical Therapeutic Chemical (ATC) Classification
In the Anatomical Therapeutic Chemical (ATC) classification system, the active substances are divided into different groups according to the organ or system on which they act and their therapeutic, pharmacological and chemical properties Drugs are classified in groups at five different levels
- WHO announces landmark changes in treatment of drug-resistant tuberculosis
The World Health Organization (WHO) today released its Consolidated guidelines on tuberculosis (TB)- Module 4: treatment and care, consolidating all previous guidelines into a single comprehensive document and introducing significant improvements in treatment options for people with multidrug-resistant or rifampicin-resistant tuberculosis (MDR RR-TB)
- WHO consolidated guidelines on tuberculosis: module 4: treatment and care
Module 4: treatment and care encompass all current recommendations for managing drug-susceptible and drug-resistant TB, alongside patient care and support strategies Developed according to WHO’s rigorous standards, the guidelines rely on the latest evidence reviews and the GRADE methodology to evaluate evidence quality and determine the strength of each recommendation Primarily aimed at
- WHO pharmaceuticals newsletter - No. 1, 2025
The WHO pharmaceuticals newsletter provides you with the latest information on the safety of medicinal products and regulatory actions taken by authorities around the world In addition, this edition includes a summary of Pharmacovigilance Partners’ Meeting held in New Delhi, India on 13 October 2024 with a synopsis of WHO Global Smart Pharmacovigilance Strategy
|
|
|